Semaglutide to Reduce Atrial Fibrillation Burden
- Status
- SuspendedStopped: Company decision
Results none - Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to no upper limit; BMI ≥27 required; conditions: Atrial Fibrillation; Obesity; Overweight
- Interventions
- Semaglutide; Placebo
- Conditions
- Atrial Fibrillation; Obesity; Overweight
- Phase and size
- Phase 4 · 132 participants
- Dates
- Start 2023-05
Primary completion 2027-05 - Sponsor
- San Francisco Veterans Affairs Medical Center (Fed)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Atrial fibrillation burden52 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Patients ≥ 18 years old with a BMI ≥ 27 kg/m2 who have paroxysmal AF with a ≥ 10% burden on ambulatory monitoring or a previous electrical cardioversion or early persistent AF (≥ 7 days, \< 3 months) who are willing to attempt rhythm control. Exclusion Criteria: * Unable to consent * A personal or family history of medullary thyroid carcinoma * A personal or family history of multiple endocrine neoplasia syndrome type 2 * History of allergic reaction to Semaglutide or any of its components * Currently pregnant or planning to become pregnant * Currently breastfeeding * History of acute pancreatitis * History of pancreatic adenocarcinoma * Previous or current GLP-1 RA use * Previous or current use of alternative pharmacologic weight loss agents (phentermine, diethylpropion, orlistat, phentermine-topiramate, bupropion- naltrexone, gelesis100, or setmelanotide) * Unable to tolerate anticoagulation * History of bariatric surgery
03Change log
Registry changes
No changes recorded since the trial was added.